Neurodevelopmental delays and neuroimaging abnormalities continue to be found in children, adolescents, and youth living with HIV despite the administration of effective combination antiretroviral therapy (cART). However, there are no clear criteria for the diagnosis of HIV-related cognitive impairment in the paediatric cohort as there are for HIV-associated cognitive disorders (HAND) in adults. Neuroimaging could be a useful tool for assessing the extent of HIV-related effects on the brain, but it is not clear how subtle deficits seen on neuroimaging are related to cognitive performance in children, adolescents and youth.

Despite declining numbers of new pediatric HIV infections and advancements in treatment for children and adolescents living with HIV (CALHIV), barriers remain. Comprehensive care for CALHIV in low- and middle-income countries is challenged by limited treatment options, unique psychosocial challenges, and caregiver reliance. Successful care relies on understanding the unique developmental needs, as well as their vulnerabilities to treatment failure and HIV drug resistance.

We examine the current understanding of the multidisciplinary aspects of hepatitis B cure research, such as socio-behavioral sciences, ethics, community engagement, and translational and implementation science.

We searched PubMed, CINAHL Plus, Embase, Scopus, Web of Science, and ERIC to identify peer-reviewed studies published between 2015 and 2025 that discussed PrEP at HBCUs. We sought to examine PrEP research, with a focus on PrEP implementation strategies, at HBCUs. Two authors reviewed titles, abstracts, and full texts against the inclusion criteria. Six articles were included in this review.

This scoping review aims to identify and characterize analytic methods used to investigate digital communication related to HIV.

People with HIV and HBV coinfection have increased risk of developing liver fibrosis and hepatocellular carcinoma (HCC) compared to either infection alone. We review current and emerging tools for HCC diagnosis and prediction in the context of HIV-HBV coinfection.

This review highlights the importance of Hepatitis B virus (HBV) integrated into the host genome (iDNA) to functional cure and how human immunodeficiency virus (HIV) may affect HBV integration.

Stimulant use, which includes use of cocaine and methamphetamine, is known to worsen care outcomes among people living with HIV (PLWH). The rise of stimulant use in the United States (US) in the last decade is a threat to the US plan of Ending the HIV Epidemic. Digital interventions - including those delivered through web- and mobile phone-based modalities - may mitigate the scale of stimulant use among PLWH, thereby disrupting HIV transmission attributable to it. We sought to understand the state of digital interventions for stimulant use among populations of PLWH, with the goal of highlighting opportunities to expand such public health responses to stimulant use.

This article presents an overview of the global consensus of the management of pregnant women living with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) co-infection. We summarise findings from the most recent and relevant literature on this topic with a focus on epidemiology, obstetric and pharmacological management and neonatal care.

Coinfection with HIV-HBV results in increased rate of liver disease progression through immune and metabolic dysfunction. Additional metabolic risks in ageing people with HIV (PwHIV) contribute to hepatic necroinflammation and fibrogenesis. There are now several blood-based and imaging non-invasive tests (NIT) that are increasingly available as an alternative to biopsy to estimate hepatic fibrosis.

Liver biopsy and FNA in persons with HIV-HBV coinfection can aid in the assessment of intrahepatic milieu, direct functional cure strategies, and facilitate development of novel therapeutics.

Death following hospitalization remains strikingly high for people living with HIV (PLHIV) in sub-Saharan Africa. Hospitalization represents a key opportunity for targeted interventions, yet evidence for effective approaches remains limited. We conducted a best-evidence narrative review, framed by the Andersen Model of Health Care Utilization, to examine factors contributing to post-hospital mortality and assess recent interventions.

This review explores the promise and challenges of integrating long-acting antiretroviral agents-cabotegravir, lenacapavir, and cabotegravir-rilpivirine-into HIV prevention and treatment programs for pregnant and breastfeeding populations. It aims to examine current evidence, implementation experiences, and barriers to equitable access.

Big Data sources, specifically electronic health records (EHR) and insurance claims data, are key in advancing HIV research. This scoping review summarizes recent research using EHR/claims to understand the evolving relationship between HIV and comorbidities.

Sexually transmitted infections (STIs) include a diverse set of bacteria, viruses, parasites, and other pathogens that can facilitate transmission of Human Immunodeficiency Virus (HIV). However, the extent to which STIs increase HIV risk and public health approaches to address this are still evolving.

Trauma is common among people living with or at risk for HIV and associated with increased HIV risk and worse HIV care outcomes. Trauma-informed care (TIC) may improve clinical interactions and support care engagement yet may be difficult to implement as a multi-component organizational intervention. We aimed to identify research on implementation of TIC in HIV prevention and treatment settings and assess barriers and facilitators to implementation.

The objective of this review is to examine the intersection of pregnancy and HIV, focusing on birthing person and fetal health outcomes, prevention of perinatal HIV transmission, and the latest advancements in treatment and care in the United States. It highlights current guidelines, challenges in management, and future directions for improving outcomes.

This update addresses HIV/TB co-infection management in pregnancy, focusing on new treatment options.

Low-level viremia (LLV) remains common in the modern HIV treatment era. We sought to clarify a unified definition of LLV, examine current LLV risk factors, assess outcomes for people with LLV, explore sex and gender differences, and evaluate management updates for people who develop LLV.

Stigma and discrimination remain critical determinants of HIV inequities among people with and vulnerable to HIV (PWAVH), as they are key drivers of HIV outcomes by restricting access to health-enabling resources.